Pfizer resumes hemophilia study after nearly yearlong pause

A serious adverse event has been investigated, and Pfizer and partner Sangamo are ready to reopen a phase III trial with hemophilia A patients.

Photo: Peter Nicholls/REUTERS / X03508

After a halt of nearly a full year, Pfizer and partner Sangamo Therapeutics have chosen to resume a phase III study of drug candidate giroctocogene fitelparvovec, a potential gene therapy for moderate-to-severe hemophilia A, Pfizer announces in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs